Allscripts Healthcare Solutions Inc (MDRX) Solutions: Worth A Shot? – Cerner Corporation (CERN)

Page 1 of 2

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) has been through a pretty rough patch. The company, which makes electronic medical record software for large healthcare organizations, has seen turmoil and turnover on its board of directors, the departure of its CEO, a stinging rebuke from major shareholders, and the possibility of throwing in the towel and selling out.

Not surprisingly, the tech vendor, which has a market cap of $1.8 billion, has seen its stock price plummet, losing 48 percent of its value over the last year. That’s something of a trick in an era when hospitals are rewarded handsomely by the government for buying EMRs, courtesy of federal legislation allocating billions in incentive bucks.

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX)

Compare that to a competitor like  Cerner Corporation (NASDAQ:CERN), and you get a picture of just what kind of market seems to be passing Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) by. Cerner Corporation (NASDAQ:CERN), which closed at $92.29 per share on March 8, has climbed from a 52-week low of $67.64 per share. Cerner Corporation (NASDAQ:CERN) has a $15.89 billion market cap, and last reported EPS of $2.26. Given its market-leading position as a vendor to hospitals, I don’t think it’s peaked yet either.

OK, so maybe it hasn’t played its hand well of late, but Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) hasn’t lost all of its fans. In fact, the high-performing Vanguard Health Fund made Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) one of its biggest investments of the year in 2012, picking up 3.8 million shares at about $12 per share. (So far, the investment is still underwater; Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) closed at $11.22 per share on February 13, still in the ballpark, but not an improvement either.)

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) rose as high as $22 per share during the past 52 weeks, so there’s reason for hope for any investor that gets in now. The question is just how much hope, given the still-stormy seas Allscripts rides on these days. Let’s break it down.

In Allscripts’ favor:

* Steady growth: Over the past five years Allscripts has seen 14.8% annual revenue growth and 19.7% for EBITDA. Free cash flow has grown a striking 82.8 percent, which is nothing to sneeze at.

Strong market position: Despite some questionable moves (such as discontinuing its physician product abruptly) which lost it some respect, Allscripts remains on the shortlist when hospitals are buying, along with giants like Cerner Corporation (NASDAQ:CERN) and privately-held colossus Epic Systems.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!